Evidence map›Paper›PMID 28691076›Full record

ArticleACS central science2017

Self-Assembling Cyclic d,l-α-Peptides as Modulators of Plasma HDL Function. A Supramolecular Approach toward Antiatherosclerotic Agents.

Yannan Zhao, Luke J Leman, Debra J Search, Ricardo A Garcia, David A Gordon, Bruce E Maryanoff, M Reza Ghadiri

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS central science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Cyclization and Self-Assembly of Cyclic Peptides.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Peptide Tectonics: Encoded Structural Complementarity Dictates Programmable Self-Assembly.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yannan ZhaoDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
Luke J LemanDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
Debra J SearchCardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey 08534, United States.
Ricardo A GarciaCardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey 08534, United States.
David A GordonCardiovascular Drug Discovery, Bristol-Myers Squibb Company, Pennington, New Jersey 08534, United States.
Bruce E MaryanoffDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
M Reza GhadiriDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States.
Scripps Research Institute · USBristol-Myers Squibb (United States) · US

Funding

Managing Atherosclerosis by Modulating HDL FunctionR01HL118114 · NHLBI · SCRIPPS RESEARCH INSTITUTE, THE · PI GHADIRI, M. REZA · 2013 to 2025
$8.5M
NHLBI NIH HHS R01 HL118114
6 · The paper itself

Abstract

There is great interest in developing new modes of therapy for atherosclerosis to treat coronary heart disease and stroke, particularly ones that involve modulation of high-density lipoproteins (HDLs). Here, we describe a new supramolecular chemotype for altering HDL morphology and function. Guided by rational design and SAR-driven peptide sequence enumerations, we have synthesized and determined the HDL remodeling activities of over 80 cyclic d,l-α-peptides. We have identified a few distinct sequence motifs that are effective

Identifiers

PMID28691076
PMCPMC5492419
OpenAlexW2626521854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.